PharmAbcine Inc. announced that the Company will present the updated data of PMC-309, one of the Company's first immuno-oncology drug candidates, at AACR (American Association for Cancer Research) 2022. The event will take place both onsite (New Orleans, Louisiana) and online over April 8-13, 2022. PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody in the development to treat various tumor types.

VISTA is an immune checkpoint receptor that is mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells). It is known to play a pivotal role in maintaining the immunosuppressive environment around the tumor cells. Due to this unique mode of action, PMC-309 can provide a promising immunotherapeutic strategy and help address unmet medical needs.